License and Agreements (Details)	1 Months Ended	12 Months Ended
	Jan. 31, 2019 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 AUD ($)	Dec. 31, 2019 USD ($) shares	Aug. 31, 2020 USD ($)	Aug. 31, 2020 AUD ($)	May 31, 2020 USD ($)	May 31, 2020 AUD ($)	Jan. 31, 2020 USD ($)	Jan. 31, 2020 AUD ($)	Dec. 24, 2019 $ / shares	Jun. 30, 2019 USD ($)	Apr. 30, 2019 USD ($)	May 31, 2018 USD ($)	Mar. 31, 2018 USD ($)
License and Agreements (Details) [Line Items]
Assignment fee							$ 953,388								$ 100,000
Milestone fee		$ 50,000
Common shares outstanding price percentage		1.00%
Amount of common shares due payable (in Shares) | shares				220,666
Fair value of common stock				$1,132,000
Closing stock price (in Dollars per share) | $ / shares											$ 5.13
Description of license and agreements				As of December 31, 2019, the Company had not paid the $50,000 or issued the shares and has included the $50,000 in accounts payable and the share amount due as a research and development expense payable. The Company paid the $50,000 and issued the shares in January 2020.
Research and development expense				$ 1,132,000
Research and development expense		$ 1,824,000		977,000
Pre-marketing approvals		25,000,000
Master Services [Member]
License and Agreements (Details) [Line Items]
Assignment fee	$ 4,582,000													$ 1,790,000
Agreement term, description	In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into a contract with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (“SPI”)) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits.
Research and development expense		1,177,000		2,746,000
Irisys, LLC [Member]
License and Agreements (Details) [Line Items]
Assignment fee													$ 3,220,000
Research and development expense		1,837,000		867,000
CoreRx [Member]
License and Agreements (Details) [Line Items]
Assignment fee												$ 1,103,000
Research and development expense		839,000		$ 290,000
Conform Clinical Development, Inc. [Member]
License and Agreements (Details) [Line Items]
Assignment fee					$ 1,484,000
Novotech (Australia) Pty Ltd [Member]
License and Agreements (Details) [Line Items]
Assignment fee									$ 1,355,580	$ 1,942,981
Research and development expense		407,000	$ 590,000
Nucleus Network Pty Ltd [Member]
License and Agreements (Details) [Line Items]
Assignment fee								$ 1,392,805
Research and development expense		337,000	489,000
Q-Pharm Pty Ltd [Member]
License and Agreements (Details) [Line Items]
Assignment fee					$ 505,488	$ 704,600
Research and development expense		$ 384,000	$ 557,000